Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | PRCP | P42785 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betaprodine SCHEMBL248367 | 0.88 | LMNA (0.97) | LMNADRD3NPSR1SLC6A4KCNH2 | |
| Betaprodine SCHEMBL186644 | 0.88 | LMNA (0.97) | LMNADRD3NPSR1SLC6A4KCNH2 | |
| Betaprodine SCHEMBL25053 | 0.88 | LMNA (0.97) | LMNADRD3NPSR1SLC6A4KCNH2 | |
| Alphaprodine SCHEMBL25054 | 0.88 | LMNA (0.97) | LMNADRD3NPSR1SLC6A4KCNH2 | |
| Alphaprodine SCHEMBL8818643 | 0.87 | LMNA (1.00) | LMNADRD3NPSR1SLC6A4KCNH2 | |
| Betaprodine SCHEMBL394431 | 0.87 | LMNA (1.00) | LMNADRD3NPSR1SLC6A4KCNH2 | |
| Betaprodine SCHEMBL1649307 | 0.86 | LMNA (0.93) | LMNADRD3NPSR1SLC6A4KCNH2 | |
| Proheptazine SCHEMBL25539 | 0.84 | LMNA (0.84) | LMNADRD3NPSR1SLC6A4KCNH2 | |
| SCHEMBL11541985 | 0.80 | LMNA (0.70) | LMNADRD3NPSR1SLC6A4KCNH2 | |
| SCHEMBL11383571 | 0.78 | LMNA (0.78) | LMNADRD3NPSR1SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421266-B2 | Safety of pseudoephedrine drug products | PISGAH LABORATORIES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-8859622-B1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140178480-A1 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS | PISGAH LABORATORIES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-8575151-B1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | Pisgah National Laboratories, Inc. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8334322-B1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | Pisgah Laboratories, LLC (US) | 2012-12-18 | — | — | US | disclosed |
| US-20090259039-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20080293695-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293695-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | SLC6A2, SLC18A2, SLC6A3 | LMNA 4559/4885DRD3 183/4885NPSR1 155/4885 |
| US-20140178480-A1 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS | SORD, ABCB11, ABCB1 | LMNA 2816/4885DRD3 305/4885NPSR1 539/4885 |
| US-20090259039-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | SLC18A2, SLC18A1, SLC6A2 | LMNA 4054/4885DRD3 148/4885NPSR1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.